Quest Diagnostics, Inc. DGX

NYS: DGX | ISIN: US74834L1008   24/10/2025
182,18 USD (-0,57%)
(-0,57%)   24/10/2025

21 oktober 2025 · Quest Diagnostics Reports Third Quarter 2025 Financial Results; Raises Guidance for Full Year 2025 · Persbericht

25 september 2025 · Quest Diagnostics to Release Third Quarter 2025 Financial Results on October 21, 2025 · Persbericht

23 september 2025 · Quest Diagnostics to Improve Laboratory Testing Experience with Industry-First Epic Collaboration · Persbericht

22 september 2025 · Haystack Oncology and Rutgers Cancer Institute Collaborate in a Clinical Study to Examine Haystack MRD as a Guide for Post-Surgical Treatment for Lung Cancer · Persbericht

16 september 2025 · Quest Diagnostics to Speak at the Jefferies Healthcare Services Conference · Persbericht

4 september 2025 · Quest Diagnostics Launches Advanced Pharmacogenomics (PGx) Offering · Persbericht

2 september 2025 · Fentanyl Positivity Is More Than Seven Times Higher in Random Tests vs. Pre-Employment Drug Screening, Finds 2025 Quest Diagnostics Drug Testing Index · Persbericht

26 augustus 2025 · Corewell Health and Quest Diagnostics to Enter into Joint Venture Providing Enhanced Laboratory Services in Michigan · Persbericht

25 augustus 2025 · FDA Grants Breakthrough Device Designation for Haystack MRD Circulating Tumor DNA Test from Quest Diagnostics · Persbericht

16 augustus 2025 · Quest Diagnostics to Speak at the Baird 2025 Global Healthcare Conference · Persbericht

14 augustus 2025 · Quest Diagnostics Declares Quarterly Cash Dividend · Persbericht

7 augustus 2025 · Mass General Brigham Launches Two Clinical Trials to Study Haystack MRD ctDNA as Guide for Post-surgical Treatment for Two Cancer Types · Persbericht

5 augustus 2025 · Quest Diagnostics Completes Acquisition of Clinical Testing Assets from Fresenius Medical Care · Persbericht

29 juli 2025 · Athena Diagnostics Improves Ataxia Movement Disorder Testing with Novel Long-Read Gene Sequencing · Persbericht

22 juli 2025 · Quest Diagnostics Reports Second Quarter 2025 Financial Results; Raises Guidance for Full Year 2025 · Persbericht

15 juli 2025 · Quest Diagnostics Introduces Testing for Oropouche Virus · Persbericht

9 juli 2025 · Quest Diagnostics to Offer FDA-Cleared Fujirebio Blood Test for Alzheimer's Disease · Persbericht

25 juni 2025 · Quest Diagnostics Releases 2024 Corporate Responsibility Report · Persbericht

23 juni 2025 · Quest Diagnostics to Release Second Quarter 2025 Financial Results on July 22, 2025 · Persbericht

10 juni 2025 · Quest Diagnostics to Develop Multi-cancer Stratification (MCaST) Blood Test Based on MD Anderson Technology · Persbericht

Mijn selecties